Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting

Pharmacotherapy

Volumn 28, Issue 1, 2008, Pages 82-89

  LaPlante, Kerry L ^a,b   Mersfelder, Tracey L ^a,b   Ward, Kristina E ^a   Quilliam, Brian J ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Azithromycin; Dysglycemias; Gatifloxacin; Hyperglycemia; Hypoglycemia; Levofloxacin; Outpatient

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; AZITHROMYCIN; CREATININE; GATIFLOXACIN; INSULIN; LEVOFLOXACIN; METFORMIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONYLUREA;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BODY MASS; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG USE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFECTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBESITY; OUTPATIENT; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CREATININE; DIABETES COMPLICATIONS; FEMALE; FLUOROQUINOLONES; HOSPITALS, VETERANS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; MALE; MEDICAL RECORDS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OFLOXACIN; PREVALENCE; RETROSPECTIVE STUDIES; RHODE ISLAND; RISK FACTORS;

EID: 38049022612     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.1.82     Document Type: Article

References (30)

1. Workowski KA, Berman SM. CDC sexually transmitted diseases treatment guidelines. Clin Infect Dis 2002;35:S135-7.
2. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity antimicrobial therapy and prevention. Am J Respir Crit Care Med 2001;163: 1730-54.
3. Drugs.com. Top 200 drugs for 2004 by U.S. sales. Available from http://www.drugs.com/top200_2004.html. Accessed October 23, 2007.
4. Maeda N, Tamagawa T, Niki I, et al. Increase in insulin release from rat pancreatic islets by quinolone antibiotics. Br J Pharmacol 1996;117:372-6.
5. + channels. Eur J Pharmacol 2004;497:111-17.
6. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354:1352-61.
7. Gavin JR III, Kubin R, Choudhri S, et al. Moxifloxacin and glucose homeostasis: a pooled analysis of the evidence from clinical and postmarketing studies. Drug Saf 2004;27:671-86.
8. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 2007;30(suppl 1):S4-41.
9. Clements S, Braithwaite SS, Magee MF, et al, on behalf of the Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals (technical review). Diabetes Care 2004;27:553-89.
10. Ortho-McNeil Pharmaceuticals, Inc. Levoquin (levofloxacin) package insert. Raritan, NJ; September 2007.
11. Bristol-Myers Squibb Company. Tequin (gatifloxacin) package insert. Princeton, NJ; July 2003.
12. Baker SE, Hangii MC. Possible gatifloxacin-induced hypoglycemia. Ann Pharmacother 2002;36:1722-6.
13. Bhatia V, Bhatia R, Dhindsa S. Gatifloxacin-induced hyperglycemia [letter]. Endocr Pract 2004;10:86.
14. Blommel AL, Lutes RA. Severe hyperglycemia during renally adjusted gatifloxacin therapy. Ann Pharmacother 2005;39: 1349-52.
15. Greenberg AL, Decerbo M, Fan J. Gatifloxacin therapy associated with hypoglycemia. Clin Infect Dis 2005;40:1210-11.
16. Khovidhunkit W, Sunthornyothin S. Hypoglycemia, hyperglycemia, and gatifloxacin [letter]. Ann Intern Med 2004;141:969.
17. Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH. Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Am J Med 2002;113:232-4.
18. Roberge RJ, Kaplan R, Frank R, Fore C. Glyburide-ciprofloxacin interaction with resistant hypoglycemia. Ann Emerg Med 2000;36:160-3.
19. Lin G, Hays DP, Spillane L. Refractory hypoglycemia from ciprofloxacin and glyburide interaction. J Toxicol Clin Toxicol 2004;42:295-7.
20. Friedrich LV, Dougherty R. Fatal hypoglycemia associated with levofloxacin. Pharmacotherapy 2004;24:1807-12.
21. Wang S, Rizvi AA. Levofloxacin-induced hypoglycemia in a nondiabetic patient. Am J Med Sci 2006;331:334-5.
22. Kanbay M, Aydogan T, Bozalan R, et al. A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient. Diabetes Care 2006;29:1716-17.
23. Blackwell T. Antibiotic suspected as factor in deaths: liver damage linked to levofloxacin. National Post [Canada]. January 4, 2007:A4.
24. Schering-Plough. Avelox (moxifloxacin) package insert [online]. Available from http://www.avelox.com. Accessed October 23, 2007.
25. United States Food and Drug Administration. Patient information sheet - gatifloxacin (marketed as Tequin). Available from http://www.fda.gov/ cder/drug/InfoSheets/ patient/gatifloxacinPIS.htm. Accessed November 11, 2006.
26. Kyorin Pharmaceutical Co., Ltd. Kyorin home page. Available from http://www.kyorin-pharm.co.jp/e. Accessed November 11, 2006.
27. Coblio NA, Mowrey K, McCright P, Means H, McCormick MT. Use of a data warehouse to examine the effect of fluoroquinolones on glucose metabolism. Am J Health-Syst Pharm 2004;61:2545-8.
28. Mohr JF, McKinnon PS, Peymann PJ, Kenton I, Septimus E, Okhuysen PC. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 2005;25:1303-9.
29. Frothingham R. Glucose homeostasis abnormalities associated with use of gatifloxacin. Clin Infect Dis 2005;41:1269-76.
30. Graumlich JF, Habis S, Avelino RR, et al. Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study Pharmacotherapy 2005;25:1296-302.